Verified by AISci
Public source attached
Source status for this paper in the current AISci reviewed snapshot.
- Primary source
- ClinicalTrials.gov
- Correction status
- none
- Evidence coverage
- 1 sources / 1 publishers
- Last metadata check
- Jul 19, 2026
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) (NCT02465060)
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) | Phase: PHASE2 | Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Bladder Carcinoma
SourceClinicalTrials.govVerified by AISci
Source status for this paper in the current AISci reviewed snapshot.
AI Reading Notes
Structured notes generated from source-linked AISci metadata. Treat them as a reading aid, not a substitute for the paper.
Research Workflow
Recommended next steps for turning this signal into research action.
No reviewed author edge is attached to this output.
No source-confirmed author affiliation is attached.
Organization linked by public source evidence.
Controlled AISci Stage A topic for Diagnostics and Biomarkers.
Clinical/translation signal: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)